Skip to content

欧力士

US · IX #545 按市值排名 上市于 1970
36.89 +0.38 +1.04%
实时 - 追踪5344个代码 - 心跳于444秒前 · 2026-10-16 19:30

最新新闻

  • IX Biopharma Rides DoD-Backed Wafermine Push and U.S. Expansion Strategy
    TipRanks · 2026/9/23
  • 公司公告
    4: Netskope | 4: Statement of changes in beneficial ownership of securities-10% Owner Lightspeed Venture Partners IX, L.P.
    SEC · 2026/7/10
  • IX Biopharma Details Wafermine Milestones and U.S. Compounding Push Ahead of AGM
    TipRanks · 2026/10/10
  • 公司公告
    4: Boundless Bio | 4: Statement of changes in beneficial ownership of securities-10% Owner ARCH Venture Fund IX, L.P.
    SEC · 2026/7/7
  • IX Biopharma Advances Wafermine as U.S. Opens Rare Military Emergency Use Pathway
    TipRanks · 2026/9/7
  • 评级变动
    Phillip Securities Remains a Buy on IX Biopharma Ltd. (42C)
    TipRanks · 2026/9/9
  • 公司公告
    ORIX: (Progress of Matters for Disclosure) Notice Regarding Transfer of Equity Interest (change in subsidiary): IX NTI Holdings (U.S. PE Investment: NC)
    JPX · 2026/6/30
  • 公司公告
    IX Biopharma: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-Cessation of Substantial Shareholder - Anson Properties Pte. Ltd.
    SGX · 2026/9/10
  • 评级变动
    BofA Securities Maintains ORIX(IX.US) With Hold Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/10
  • Analyst Maintains Buy on IX Biopharma, Sees Post-FY26 Transition Driving Strong FY27+ Rebound and Keeps DCF-Based S$1.00 Target Price
    TipRanks · 2026/9/1
  • IX Biopharma Moves to Convert A$1.7 Million Debt Into Equity
    TipRanks · 2026/10/5
  • 公司公告
    Netskope | 4: Statement of changes in beneficial ownership of securities-10% Owner Lightspeed Venture Partners IX, L.P.
    SEC · 2026/9/15
  • 评级变动
    BofA Securities Initiates ORIX(IX.US) With Hold Rating
    \u5e02\u573a\u8d44\u8baf · 2024/11/12
  • AXP Energy Exits Syrian Block IX Farm-In to Refocus on U.S. Operations
    TipRanks · 2026/8/31

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

欧力士 讨论区 0 条评论

发表评论